In a meeting on 2nd of July 2026 in Amsterdam, the EMA demonstrated its willingness to keep all relevant regulatory data secret, raising questions why scientific re-assessment is made impossible.
The EMA’s review process is intended to protect citizens in Europe from harmful medicines, not the manufacturers. We need either the assurance that everything was above board or the certainty that the EMA accepted the risk of illnesses—and even death.
The EMA’s review process is intended to protect citizens in Europe from harmful medicines, not the manufacturers. We need either the assurance that everything was above board or the certainty that the EMA accepted the risk of illnesses—and even death.